MedTrace Logo

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

NCT01633788 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2017-09-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.

Conditions

  • Meibomian Gland Dysfunction

Interventions

DRUG

AGN-195263 0.1%

1 drop of AGN-195263 0.1% instilled in each eye twice daily.

DRUG

AGN-195263 0.03%

1 drop of AGN-195263 0.03% instilled in each eye twice daily.

DRUG

AGN-195263 0.01%

1 drop of AGN-195263 0.01% instilled in each eye twice daily.

DRUG

AGN-195263 Vehicle

1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-22
Primary Completion
2015-02-05
Completion
2015-02-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633788 on ClinicalTrials.gov